Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada

References

• Tang AS, Ross H, Simpson CS, et al. Canadian Heart Rhythm Society; Canadian Cardiovascular Society. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol 2005;21 (Suppl A):11A-8A
   Google Scholar
• Task Force of the European Society of Cardiology and the European Resuscitation Council. The pre-hospital management of acute heart attacks. Eur Heart J 1998;19:1140-64
   PubMed Web of Science ®Google Scholar
• Birnie DH, Sambell C, Johansen H, et al. Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. CMAJ 2007;177:41-6
   PubMed Web of Science ®Google Scholar
• Parkes J, Chase DL, Grace A, et al. Inequity of use of implantable cardioverter defibrillators in England: retrospective analysis. BMJ 2005;330:454-5
   PubMed Web of Science ®Google Scholar
• Talajic M, Mitchell LB, Hadjis T. The role of prophylactic implantable cardioverter defibrillators to prevent sudden cardiac death. Can J Cardiol 2000;6 (Suppl C):26C-8C
   Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37
   Google Scholar
• Nanthakumar K, Epstein A, Kay G, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:2166-72
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-e484
   PubMed Web of Science ®Google Scholar
• Parkash R, Tang A, Wells G, et al. Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. CMAJ 2004;171:1053-6
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007;298:1525-32
   PubMed Web of Science ®Google Scholar
• Drummond ME, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2005
   Google Scholar
• Larsen G, Hallstrom A, McAnulty J, et al, AVID Investigators. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis sub-study. Circulation 2002;105:2049-57
   PubMed Web of Science ®Google Scholar
• Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter defibrillators. N Engl J Med 2005;353:1471-80
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward A, Deniz HB, et al. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone. Value Health 2007;10:13-22
   PubMed Web of Science ®Google Scholar
• Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA, 3rd edn. Boston: McGraw-Hill, 2003
   Google Scholar
• Krahn AD, Connolly SJ, Roberts RS, Gent M; ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004;147:837-40
   Google Scholar
• Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24
   PubMed Web of Science ®Google Scholar
• Guglin ME, Wilson A, Kostis JB, et al. Immediate and 1-year survival of out-of-hospital cardiac arrest victims in southern New Jersey: 1995-2000. Pacing Clin Electrophysiol 2004;27:1072-6
   PubMed Web of Science ®Google Scholar
• Parkash R, Tang A, Wells G, et al. Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. CMAJ 2004;171:1053-6
   PubMed Web of Science ®Google Scholar
• Stiell IG, Wells GA, Field B, et al.; Ontario Pre-hospital Advanced Life Support Study Group. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med 2004; 351:647-56
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Circulation. 2006;114:e385-e484
   PubMed Web of Science ®Google Scholar
• Drug Facts and Comparisons, 57th edn. Facts and Comparisons. American Journal of Pharmaceutical Education, 2003 (St. Louis, MO)
   Google Scholar
• Carson RT. Contingent Valuation: A User's Guide. Environ Sci Technol 2000;34:1413-18
   Web of Science ®Google Scholar
• Mitchell R, Carson R. Using Surveys to Value Public Goods: the Contingent Valuation Method. Baltimore: Johns Hopkins University Press, 1989
   Google Scholar
• Health Canada Reports and Publications. Regulatory Impact Analysis Statement for the proposed Cigarette Ignition Propensity Regulations and Proposed Regulations Amending the Tobacco Reporting Regulations. Available from: http://www.hc-sc.gc.ca/hl-vs/pubs/tobac-tabac/rias-reir/index_e.html [Last accessed 9 December 2007]
   Google Scholar
• Ontario Ministry of Health and Ontario Hospital Association Partnership: Joint Policy and Planning Committee. A methodology for costing and an approach to funding pacemakers and implantable cardioverter defibrillators. Final report. 1999. Available from: www.jppc.org/library/priority/rd7_8.pdf [Last accessed 16 January 2008]
   Google Scholar
• Ontario Drug Benefit Formulary/Comparative Drug Index No. 39. Available from: www.health.gov.on.ca/english/providers/program/drugs/formulary/ed39_0_bk.pdf [Last accessed 12 December 2007]
   Google Scholar
• Alberta Health and Wellness Publications. Health Costing in Alberta, 2006 Annual Report. Available from: http://health. gov.ab.ca/resources/publications/Health_Costing_2006.pdf [Last accessed 12 December 2007]
   Google Scholar
• HM Treasury UK Publications. Available from: www.hm-treasury.gov.uk/media/0/B/Managing_risks_to_the_public.pdf [Last accessed 12 December 2007]
   Google Scholar
• Alberini A, Hunt A, Markandya A. Willingness to pay to reduce mortality risks: evidence from a three country contingent valuation study. September 2004. FEEM Working Paper No. 111.04. Available from: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=593661 [Last accessed 14 January 2008]
   Google Scholar
• Viscusi WK. The value of risks to life and health. J Econ Lit 1993;31:1912-46
   Web of Science ®Google Scholar
• US Department of Transportation. Office of Economic and Strategic Analysis. Revision of Departmental Guidance on Treatment of the Value of Life and Injuries. Available from: http://ostpxweb.dot.gov/policy/EconStrat/treatmentoflife.htm [Last accessed 12 December 2007]
   Google Scholar
• Miller T, Levy DT. Cost-outcome analysis in injury prevention and control: eighty-four recent estimates for the United States. Med Care 2000;38:562-82
   PubMed Web of Science ®Google Scholar
• Viscusi WK, Hakes JK, Carlin A. Measures of mortality risk. J Risk Uncertainty 1997;14:213-33
   Web of Science ®Google Scholar
• Ekwueme DU, Strebel PM, Hadler SC, et al. Economic evaluation of use of diphtheria, tetanus, and a cellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000;154:797-803
   PubMed Web of Science ®Google Scholar
• US Government, Office of Management and Budget. Ranking Regulatory Investments in Public Health. Available from: http://www.whitehouse.gov/omb/inforeg/spec24.pdf [Last accessed 12 December 2007]
   Google Scholar
• Menzel P, Gold MR, Nord E, et al. Toward a broader view of values in cost-effectiveness analysis in health. Hastings Cent Rep 1999;29:7-15
   PubMed Web of Science ®Google Scholar
• Menzel P. How should what Economists Call ‘Social Values’ be Measured? Prepared for the Society for Ethics, meeting at the Pacific Division. American Philosophical Association, Berkeley, CA, 1 April 1999. Available from: http://www.nyu.edu/gsas/dept/philo/courses/bioethics/Papers/SocForEthicsJuly99.pdf [Last accessed 15 February 2006]
   Google Scholar
• Noyes K, Corona E, Zwanziger J, et al. Multicenter Automatic Defibrillator Implantation Trial II. Health-related quality of life consequences of implantable cardioverter defibrillators: Results from MADIT II. Med Care 2007;45:377-85
   Google Scholar
• Sola CL, Bostwick JM. Implantable cardioverter-defibrillators, induced anxiety, and quality of life. Mayo Clin Proc 2005;80:232-7
   PubMed Web of Science ®Google Scholar
• Sears, SF, Conti, JB. Understanding ICD shocks and storms: Medical and psychosocial considerations for research and clinical care. Clin Cardiol 2003;26:107-11
   PubMed Web of Science ®Google Scholar
• Klug D; Balde M, Pavin D, et al., for the PEOPLE’ Study Group. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators results of a large prospective study. Circulation 2007;116:1349-55
   PubMed Web of Science ®Google Scholar
• Tandri H, Griffith LS, Tang T, et al. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm 2006;3:762-8
   PubMed Web of Science ®Google Scholar